In 2013, Finan et al. demonstrated that unimolecular dual incretin administered to rodent models of obesity and diabetes improved insulin sensitivity and increased pancreatic insulin deficiency, corrected hyperglycemia and adiposity-induced insulin resistance, and lowered body weight [109]. The gene discussed is INS; the disease is obesity disorder.